Document is current
Any future updates will be listed below
-
Authors
Jouneau, Stéphane https://orcid.org/0000-0002-1949-3461
Chauvin, Pierre
Lederlin, Mathieu
Painvin, Benoît
Kerjouan, Mallorie
-
Funding
Funding for this research was provided by:
Centre Hospitalier Universitaire de Rennes
- License Information
-
More Information
Article History
Received: 9 January 2025
Accepted: 12 August 2025
First Online: 27 August 2025
Declarations
:
: Over the past 5 years, Stéphane Jouneau declares conflicts of interest in relation to the subject of this article as he was a primary investigator in IMPALA trials and a co-author of the international guidelines on PAP management, and outside of patients with aPAP, Stéphane Jouneau has declared links with the following pharmaceutical companies (or similar): clinical research: AIRB, Astra Zeneca, Biogen, BMS, Boehringer Ingelheim, Galacto, GSK, Pliant Therapeutics, Roche, and United Therapeutics; advisory boards, consultancy: AIRB, Boehringer Ingelheim, GSK, and Sanofi; courses, training: AIRB, Astra Zeneca, BMS, Boehringer Ingelheim, Chiesi, GSK, LVL, Novartis, Pfizer, Roche, and Sanofi; and research grants: AIRB and Boehringer Ingelheim. Over the past 5 years, Pierre Chauvin reports no conflicts of interest related to the subject of this article. However, he declares affiliations with the following pharmaceutical companies (or related entities): Boehringer Ingelheim, GSK, MSD, Pfizer, Takeda France, Fujifilm France, and Novatech SA. Over the past 5 years, Mathieu Lederlin reports no conflicts of interest related to the subject of this article. However, he declares affiliations with the following pharmaceutical companies (or related entities): Boehringer Ingelheim, Sanofi, Sophia Genetics, and AstraZeneca. Over the past 5 years, Benoît Painvin reports no conflicts of interest related to the subject of this article or outside of it. Over the past 5 years, Mallorie Kerjouan reports no conflicts of interest related to the subject of this article. However, she declares affiliations with the following pharmaceutical companies (or related entities): Boehringer Ingelheim, Grifols, CSL Behring, LFB, SOS, and Oxygène.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: SJ has written the first draft of the manuscript, all authors have read and amended the manuscript. All authors have read and approved the final version of the manuscript, and agree to be accountable for the work.
